Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2133.1974.tb06429.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Halcinonide activates smoothened to ameliorate ischemic stroke injury.
Life Sci
January 2025
School of Pharmacy, Lanzhou University, Lanzhou 730000, PR China; State Key Laboratory of Veterinary Etiological Biology, College of Veterinary Medicine, Lanzhou University, Lanzhou 730000, PR China; Southeast Research Institute, Lanzhou University, Lanzhou 730000, PR China. Electronic address:
Objectives: The Shh pathway may shed new light on developing new cell death inhibitors for the therapy of ischemic stroke. We aimed to examine whether the Shh co-reporter SMO or its agonist halcinonide can upregulate Bcl-2 to suppress neuronal cell death, ultimately improving behavioral deficits and reducing cerebral infarction in an ischemic stroke model.
Methods: Halcinonide or genetic manipulation of SMO was conducted in PC12 cells to examine their impacts on oxidative or OGD/R stress, and the chemical, along with AAV-SMO or AAV-EGFP were tested in MCAO rats to investigate their potential protective effects against neuronal damages due to cerebral I/R injury.
Single-Atom Catalysts with Isolated Cu-N Sites for Atopic Dermatitis Cascade Catalytic Therapy via Activating PPAR Signaling.
Small
December 2024
Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, 200050, China.
Article Synopsis
- * A new single-atom catalyst, Cu-N ISAC, has been developed to mimic three types of antioxidant enzymes, effectively reducing harmful reactive oxygen species (ROS) and protecting skin cells from oxidative stress damage.
- * In experiments, Cu-N ISAC demonstrated better efficacy than the standard treatment, showing potential for reducing inflammation and enhancing PPAR signaling, which could help in treating AD and other related conditions.
Dual-Site Biomimetic Cu/Zn-MOF for Atopic Dermatitis Catalytic Therapy via Suppressing FcγR-Mediated Phagocytosis.
J Am Chem Soc
February 2024
Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, Clinical Center For Brain And Spinal Cord Research, School of Medicine, Tongji University, Shanghai 200331, China.
Article Synopsis
- Atopic dermatitis (AD) is a common inflammatory skin disease with high economic costs, linked to elevated levels of reactive oxygen species (ROS) that can worsen symptoms.
- Researchers developed a biomimetic copper/zinc metal-organic framework (Cu/Zn-MOF) that acts like natural enzymes, specifically targeting the signaling pathways that lead to inflammation and oxidative stress in AD.
- Animal studies show Cu/Zn-MOF is more effective than traditional steroid treatments in reducing skin damage and inflammation while demonstrating good safety, offering a promising new approach for AD therapy.
Identification and structural characterization of major stress degradation products of halcinonide by liquid chromatography-high-resolution mass spectrometry.
Biomed Chromatogr
November 2023
Opposite Air Force Station, National Institute of Pharmaceutical Education and Research-Ahmedabad (Ministry of Chemicals and Fertilizers, Government of India), Gandhinagar, Gujarat, India.
Halcinonide is a topical corticosteroid approved by the US Food and Drug Administration (FDA), known for its anti-inflammatory and antipruritic properties. The therapeutic benefits of halcinonide have rendered it an effective treatment regimen for various dermatological conditions such as psoriasis, dermatitis, and eczema. However, stability of the drug substance is a prerequisite in determining the therapeutic efficacy and plays a crucial role during formulation development and long-term storage.
View Article and Find Full Text PDFBackground: This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients.
Methods: Adults (age greater than or equal to 18 years) with moderate to severe plaque psoriasis (body surface area [BSA] greater than or equal to 10%, physician's global assessment [PGA] greater than or equal to 3, psoriasis area severity index [PASI] greater than or equal to 12) received tildrakizumab (100 mg; s.c.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!